Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells

Neuro-Oncology

Volumn 12, Issue 8, 2010, Pages 765-775

  Yan, Wei ^a   Qian, Chunfa ^a   Zhao, Peng ^a   Zhang, Junxia ^a   Shi, Lei ^b   Qian, Jin ^c   Liu, Ning ^a   Fu, Zhen ^a   Kang, Chunshen ^d   Pu, Peiyu ^d   You, Yongping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^c People's Hospital of Xuancheng   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; Invasion; Osteopontin; siRNA; Splice varant; Synonymous mutant

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ISOPROTEIN;

APOPTOSIS; ARTICLE; CELL INVASION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; BRAIN TUMOR; CANCER INVASION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; OSTEOPONTIN; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 78149479648     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq006     Document Type: Article

References (26)

1. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res. 2004;121:228-241.
2. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest. 1995;72:55-63.
3. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res. 2008;14:293-298.
4. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splice. Trends Genet. 2008;24:7-10.
5. Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics. 1990;7:491-502.
6. Kasugai S, Zhang Q, Overall CM, Wrana JL, Butler WT, Sodek J. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Miner. 1991;13:235-250.
7. He B, Mirza M,Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006;25:2192-2202.
8. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361-6371.
9. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008;122(4):889-897.
10. Zhao J, Jin J, Zhang X, et al. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo. Cancer Gene Ther. 2006;13:420-427.
11. Jang T, Savarese T, Low HP, et al. Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol. 2006;168:1676-1685.
12. Toy H, Yavas O, Eren O, Genc M, Yavas C. Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol Oncol Res. 2009;15(2):203-207.
13. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107: 1055-1061.
14. O'Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today. 2000;21:475-478.
15. Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol. 2007;81:1504-1511.
16. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol. 1998;141:1083-1093.
17. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007;67(5):2089-2097.
18. Gao C, Guo H, Wei J, Kuo PC. Osteopontin inhibits expression of cytochrome C oxidase in RAW 264.7 murine macrophages. Biochem Biophys Res Commun. 2003;309:120-125.
19. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18:157-164.
20. Suen D-F, Norris DL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev. 2008;22:1577-1590.
21. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103-118.
22. Tuck AB, Arsenault DM, O'Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 1999;18:4237-4246.
23. Ding Q, Stewart J, Jr, Prince CW, et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res. 2002;62:5336-5343.
24. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) downregulates these pathways. J Biol Chem. 2003;278(16):14487-14497.
25. Das R,MahabeleshwarGH, Kundu GC.Osteopontin stimulates cellmotility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem. 2003;278(31):28593-28606.
26. Lamour V, Le Mercier M, Lefranc F, et al. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer. 2009; doi:10.1002/ijc.24751 [published online ahead of print July 16, 2009].